A Phase 2 interventional study of zagociguat 15mg and zagociguat 30mg in Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome), sponsored by Tisento Therapeutics. Completed at 20 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Tisento Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Acidosis, Lactic with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Acidosis, Lactic · United States.
Among the 19 studies in Acidosis, Lactic with a site in United States, this one is the 2nd largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2024, is one of 6 in phase 2, and was the 17th registered.
48 studies on the registry are indexed under Acidosis, Lactic; 5 are open to participants now.
Browse Acidosis, Lactic studies →2 of the 19 studies in Acidosis, Lactic with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States, Canada
Healthy volunteers
George Washington University · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Acidosis, Lactic studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7
First in 1978; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is above the median of 39 across 26 interventional studies indexed under Acidosis, Lactic.
Median enrollment 29 across the 14 interventional studies, 35 across the 5 observational. Of the 12 that completed or were terminated, 5 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 19 have an industry lead sponsor. The 10 most frequent:
Tisento Therapeutics is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.
Tisento Therapeutics has 2 studies filed under Acidosis, Lactic — fewer than ten, so there is no comparison to draw.
1 of the studies in Acidosis, Lactic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01694940Columbia UniversityNorth American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Acidosis, Lactic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
PRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs. placebo when administered daily for 12 weeks in participants with genetically and phenotypically defined MELAS.
The goal of this clinical trial is to learn about the effectiveness of zagociguat in patients with MELAS. The main questions it aims to answer are:
The PRIZM study is evaluating 2 dose levels of zagociguat in a crossover design consisting of two 12-week treatment periods separated by a 4-week washout. Patients will be screened and if eligible, randomly assigned either to receive placebo in period 1 followed by active drug in period 2 OR to receive active drug in period 1 followed by placebo in period 2. Study medication is a once daily oral tablet and will be provided at the clinic and/or shipped to the participant's home. Clinic visits will occur at screening and Week 1 and Week 12 of each treatment period. Visits at Week 4 and Week 8 of both crossover periods will either be in clinic or optionally at the participant's home. Study assessments will be conducted weekly on a phone app and a separate tablet and additional assessments will be conducted during visits. Patients who complete the study will be eligible for an open label extension study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosed with MELAS based on the presence of each of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants first receive placebo once a day for 12 weeks. Then after a 4 week washout, they receive zagociguat 15 mg once a day for 12 weeks.
Drug: zagociguat 15mg · Drug: Placebo
Participants first receive zagociguat 15 mg once a day for 12 weeks. Then after a 4-week washout, they receive placebo once a day for 12 weeks.
Drug: zagociguat 15mg · Drug: Placebo
Participants first receive placebo once a day for 12 weeks. Then after a 4-week washout, they receive zagociguat 30 mg once a day for 12 weeks.
Drug: zagociguat 30mg · Drug: Placebo
Participants first receive zagociguat 30 mg once a day for 12 weeks. Then after a 4-week washout, they receive placebo once a day for 12 weeks.
Drug: zagociguat 30mg · Drug: Placebo
Once-daily oral tablets
Also known as: IW-6463, CY6463
Once-daily oral tablets
Also known as: IW-6463, CY6463
Once-daily oral tablets
• PROMIS Fatigue MELAS Short Form scores• Groton Maze Learning Test scores • International Digit Symbol Substitution Test scores
These measures are a patient reported questionnaire on MELAS-specific fatigue and 2 cognitive performance tests. These 3 outcome measures will be combined using a global statistical test.
Time frame: Weeks 9 through 12 of each treatment period
Incidence of Treatment-emergent Adverse Events (TEAEs)
TEAEs are any untoward event that may or may not be related to study medication.
Time frame: Weeks 1 through washout for treatment period 1 and Weeks 1 through follow-up for treatment period 2
Number of repetitions completed during the 30-second sit-to-stand test
Leg strength and exercise intolerance
Time frame: Week 12
PROMIS Cognitive Function MELAS Short Form (PCFM-SF) score
Patient-reported questionnaire on MELAS-specific cognitive function
Time frame: Week 12
Plasma concentrations of GDF-15
Measure of disease pathophysiology
Time frame: Week 12
Memory composite scores (One Card Learning and One Back Tests) for Week 9 through 12
Test of memory
Time frame: Week 9 through 12
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2024 to primary completion in Jun 2026, 21 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zagociguat
Tisento Therapeutics